)
Visual
test
Zura Bio
Zura Bio (ZURA) investor relations material
Zura Bio Q4 2025 earnings summary
Complete event summary combining all related documents: earnings call transcript, report, and slide presentation.Q4 2025 earnings summary19 Mar, 2026
Executive summary
Advanced two Phase 2 studies for tibulizumab in hidradenitis suppurativa and systemic sclerosis, with key data readouts expected in late 2026 and early 2027.
Strengthened leadership with new CEO and board appointments in early 2026.
Completed a $144 million public offering in February 2026, extending operational runway through at least end of 2028.
Financial highlights
Cash and cash equivalents were $109.4 million as of December 31, 2025, down from $176.5 million at year-end 2024.
Net loss for 2025 was $68.7 million, compared to $52.4 million in 2024.
Net loss attributable to Class A shareholders was $99.4 million, or $(1.06) per share, versus $45.4 million, or $(0.60) per share, in 2024.
R&D expenses rose to $42.1 million from $24.4 million year-over-year, mainly due to Phase 2 clinical program advancement.
G&A expenses increased to $33.2 million from $30.8 million year-over-year.
Outlook and guidance
Cash position, including proceeds from the February 2026 offering, is expected to fund operations through at least the end of 2028.
Topline data from Phase 2 TibuSHIELD (HS) expected Q4 2026; TibuSURE (SSc) data expected H1 2027.
Rationale for TibuSHIELD enrollment expansion
Details on the BAFFX17 settlement impact
Future plans for crebankitug and torudokimab
Partial view of Summaries dataset, powered by Quartr API
AI can get things wrong. Verify important information.Research faster. Power your platform.
Latest events from Zura Bio
- Pivotal phase II data for tibulizumab in HS expected Q4, with SSc data in 2027.ZURA
Leerink Global Healthcare Conference 202613 Mar 2026 - First-in-class dual-pathway antibody in Phase 2 for HS and SSc, with data expected 2026–2027.ZURACorporate presentation10 Mar 2026
- Pivotal phase II data for tibulizumab in HS and SSc expected within 12-18 months.ZURAGuggenheim Securities Emerging Outlook: Biotech Summit 202611 Feb 2026
- First-in-class dual-pathway antibody in Phase 2 for HS and SSc, targeting major unmet needs.ZURACorporate presentation11 Feb 2026
- Dual pathway biologics advance to pivotal trials in high-need autoimmune indications.ZURAH.C. Wainwright 26th Annual Global Investment Conference 202420 Jan 2026
- Advancing dual-pathway immunology assets with phase II trials and strong cash position.ZURAStifel 2024 Immunology and Inflammation Virtual Summit20 Jan 2026
- Phase II trials for novel autoimmune therapies begin in late 2024, leveraging unique antibody designs.ZURA2024 Cantor Fitzgerald Global Healthcare Conference20 Jan 2026
- Pivotal Phase II trials for SSc and HS to start soon, with readouts expected in 2026.ZURAGuggenheim Inaugural Global Healthcare Innovation Conference14 Jan 2026
- Major 2025 catalysts and robust study designs drive a focused, bispecific antibody pipeline.ZURAPiper Sandler 36th Annual Healthcare Conference12 Jan 2026
Next Zura Bio earnings date
Q1 202614 May, 2026
Zura Bio
Next Zura Bio earnings date
Q1 202614 May, 2026
The essential earnings season companion
The #1 app for qualitative research. Live earnings calls, AI chat, transcripts, and more. All for free.
Live calls and transcripts
Listen to earnings calls, CMDs, investor conferences, and more – with a podcast-like experience.
Find what you need faster
Search for any keyword across all transcripts simultaneously.
Easily store key findings
Capturing important takeaways is as simple as it gets. Even during your lunch run or commute.
Your watchlist. Your dashboard.
Follow the companies that matter to you. Get a personalized feed with real-time updates.
Be the first to know
Set keyword alerts for any company, product, or competitor. Get notified the moment they're mentioned.
Consensus estimates
Access analyst consensus estimates, valuation multiples, and revenue segments splits.
All IR material in one place
The easiest way to stay updated during earnings season.
Global coverage
All events from public companies. Live and recorded.
Just click and listen
No webcast links. No manual registrations.
excellent app, it gives me free access to company earnings calls and annual reports. I also love the convenience of calls being available offline so I can listen in whilst doing other things and even when internet or WiFi isn't available.
)
Leroy DaleyApp Store
One of the very few apps you could call perfect. If something was to add to it, maybe the share price of the company when you search for it, but it's already excellent.
)
Eferix Drawings Google Play
This is genuinely one of the cleanest and fastest finance apps out there to track the market.
anuj283App Store
excellent app, it gives me free access to company earnings calls and annual reports. I also love the convenience of calls being available offline so I can listen in whilst doing other things and even when internet or WiFi isn't available.
Leroy DaleyApp Store
One of the very few apps you could call perfect. If something was to add to it, maybe the share price of the company when you search for it, but it's already excellent.
Eferix Drawings Google Play
This is genuinely one of the cleanest and fastest finance apps out there to track the market.
anuj283App Store
I can't remember the last time an app had such a positive impact on my investment process.
)
@ankurshah47_ x.com
Love the app! Quartr makes it really easy to keep track of earnings calls. It also includes the reports and slides to make it easier to follow along.
Amina0781App Store
Quartr is amazing, no way around it. It is the best right now for earnings calls, presentations, and the like.
@theshortbearx.com
I can't remember the last time an app had such a positive impact on my investment process.
@ankurshah47_ x.com
Love the app! Quartr makes it really easy to keep track of earnings calls. It also includes the reports and slides to make it easier to follow along.
Amina0781App Store
Quartr is amazing, no way around it. It is the best right now for earnings calls, presentations, and the like.
@theshortbearx.com
)
)
Frequently asked questions
Explore our global coverage